Peripartum cardiomyopathy is an idiopathic systolic heart failure occurring late in pregnancy or early postpartum that requires multidisciplinary management and careful medication selection.
Peripartum cardiomyopathy is a form of idiopathic systolic heart failure requiring management aligned with non-ischemic cardiomyopathy guidelines, with special attention to fetal safety.
Peripartum cardiomyopathy is a form of idiopathic systolic heart failure which occurs during the end of pregnancy or the early post-partum in the absence of an identifiable etiology. The exact pathogenesis remains unknown, and the incidence is higher in African ancestry, multiparous and hypertensive women, or older maternal age. Delay in diagnosis is common, mainly because symptoms of heart failure mimic those of normal pregnancy. Echocardiography showing decreased myocardial function is at the center of the diagnosis. Management relies on the general guidelines of management of other forms of non-ischemic cardiomyopathy; however, special attention should be paid when choosing medications to ensure fetal safety. Outcomes can be variable and can range from complete recovery to persistent heart failure requiring transplant or even death. High rates of relapse with subsequent pregnancies can occur, especially with incomplete myocardial recovery. Additional research about the etiology, experimental drugs, prognosis, and duration of treatment after recovery are needed.
Iorgoveanu et al. (Thu,) conducted a review in Peripartum cardiomyopathy. Peripartum cardiomyopathy is an idiopathic systolic heart failure occurring late in pregnancy or early postpartum that requires multidisciplinary management and careful medication selection.